You have accessJournal of UrologyProstate Cancer: Advanced III1 Apr 2010862 RISEDRONATE PREVENTS EARLY BONE LOSS AND INCREASED BONE TURNOVER IN THE FIRST 6 MONTHS OF LUTEINIZING HORMONE RELEASING HORMONE AGONIST THERAPY FOR PROSTATE CANCER Pamela Taxel, Robert Dowsett, Lee Richter, Pamela Fall, Alison Kleppinger, and Peter Albertsen Pamela TaxelPamela Taxel West Hartford, CT More articles by this author , Robert DowsettRobert Dowsett Farmington, CT More articles by this author , Lee RichterLee Richter Washington, DC More articles by this author , Pamela FallPamela Fall Farmington, CT More articles by this author , Alison KleppingerAlison Kleppinger Farmington, CT More articles by this author , and Peter AlbertsenPeter Albertsen Farmington, CT More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2010.02.1618AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Of the 2 million men with prostate cancer in the United States, more than 600,000 are treated with Luteinizing Hormone Releasing Hormone (LHRH) agonists each year. These agents have been shown to cause rapid bone loss, with annual bone mineral density (BMD) losses of 0.6% to 4.6%; the most significant loss being within the first year of therapy. Furthermore, ADT has been shown to be an independent risk factor for fractures in these men. Despite this evidence, most patients receiving ADT do not receive therapy aimed at preventing related bone loss. Several studies have shown that intravenous bisphosphonates can prevent ADT induced bone loss. However, no data exists on the impact of an oral agent, administered at the onset of treatment, in preventing LHRH agonist related bone loss. This study was designed to determine if early bone loss could be prevented using a weekly oral bisphosphonate in men initiating ADT. METHODS A six-month randomized, double-blind, placebo-controlled trial was conducted in order to determine whether increased bone loss and bone turnover during the first 6 months of LHRH-agonist therapy could be prevented by bisphosphonate therapy with risedronate 35 mg/week. Forty men over age 55 beginning a 6-month course of LHRH-agonist therapy for locally advanced prostate cancer were enrolled in the study. BMD of the lumbar spine, femoral neck, and total hip was measured at baseline and after 6 months in risedronate and control groups. In addition, bone turnover markers were measured at baseline and 6 months. RESULTS After 6 months of LHRH-agonist therapy, the risedronate group showed no change in the femoral neck and total hip BMD, while the BMD in these areas in the control group decreased by 2.0 and 2.2% respectively. Markers of bone turnover were increased significantly in the control group but were unchanged in the risedronate group. CONCLUSIONS LHRH-agonist treatment for locally advanced prostate cancer produces increased bone turnover and rapid bone loss within the initial six months of therapy. Weekly oral risedronate treatment can prevent this bone loss. It can be considered an effective method to maintain bone health when initiating ADT in men with locally advanced prostate cancer. © 2010 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 183Issue 4SApril 2010Page: e336-e337 Advertisement Copyright & Permissions© 2010 by American Urological Association Education and Research, Inc.MetricsAuthor Information Pamela Taxel West Hartford, CT More articles by this author Robert Dowsett Farmington, CT More articles by this author Lee Richter Washington, DC More articles by this author Pamela Fall Farmington, CT More articles by this author Alison Kleppinger Farmington, CT More articles by this author Peter Albertsen Farmington, CT More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...